Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xilio Therapeutics (XLO) Accounts Payables (2024 - 2025)

Xilio Therapeutics (XLO) has disclosed Accounts Payables for 2 consecutive years, with $3.2 million as the latest value for Q4 2025.

  • Quarterly Accounts Payables rose 23.08% to $3.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.2 million through Dec 2025, up 23.08% year-over-year, with the annual reading at $3.2 million for FY2025, 23.08% up from the prior year.
  • Accounts Payables hit $3.2 million in Q4 2025 for Xilio Therapeutics, up from $2.3 million in the prior quarter.
  • In the past five years, Accounts Payables ranged from a high of $4.1 million in Q2 2025 to a low of $746000.0 in Q1 2024.